Cellarity, a Cambridge, Mass.-based life sciences company developing a new method of drug discovery targeting the cell, raised $123m in Series B financing.
The round included contributions from funds and accounts managed by BlackRock, The Baupost Group, Banque Pictet on behalf of their clients and eight other investors alongside Flagship Pioneering.
Founded in 2017 within Flagship Labs, Cellarity is designing medicines against the cell as opposed to a single molecular target. The company has developed a combination of expertise across system and network biology, high-resolution data, and machine learning to unlock treatments in a large number of therapeutic areas.
The company is led by Fabrice Chouraqui, CEO of Cellarity and a CEO-Partner at Flagship Pioneering.
FinSMEs
25/02/2021